VDAC2 and cancer: Erastin‐VDAC2 interaction inhibits the permeability of VDAC2 to endogenous substrates, such as NADH and decrease the NADH oxidation in cancer cells, which induces mitochondrial dysfunction and the release of oxidative species (Figure 1).